AIP
CYTK icon

Arrowpoint Investment Partners’s Cytokinetics CYTK Stock Holding History

Arrowpoint Investment Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$753K Buy
8,836
+1,448
+20% +$104K 0.16% 61
2026
Q1 		$487K Buy
7,388
+2,908
+65% +$185K 0.43% 43
2025
Q4 		$285K Buy
+4,480
New +$279K 0.04% 87

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowpoint Investment Partners's CYTK Position: Q2 2026 in Review

Arrowpoint Investment Partners increased its Cytokinetics (CYTK) stake by 20% in Q2 2026, buying an estimated $104K and bringing the position to 8,836 shares worth $753K. The position accounts for 0.16% of the portfolio, ranked #61.

Arrowpoint Investment Partners first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Arrowpoint Investment Partners held 8,836 shares of Cytokinetics worth $753K as of Q2 2026.
  • Arrowpoint Investment Partners bought 1,448 Cytokinetics shares in Q2 2026, an estimated $104K.
  • Cytokinetics made up 0.16% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #61 holding.
  • Arrowpoint Investment Partners first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.